article

Expert view: GenScript’s unique four-tier platform for successful synthesis of challenging neoantigen peptides for precision medicine

Posted: 1 June 2020 | | No comments yet

Despite hundreds of off-the-shelf treatments, cancer remains the second leading cause of death globally.

Given this drastic statistic, researchers are developing personalised immunotherapies that, as opposed to one-size-fits-all approaches, train a patient’s immune system to attack and kill their own cancerous tissue based on individualised tumour biomarkers known as neoantigens. Unlike common tumour-associated antigens, neoantigens are only expressed in cancer and are therefore highly immunogenic.











To read this expert view in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: GenScript

Send this to a friend